SCM
Silverarc Capital Management Portfolio holdings
AUM
$489M
1-Year Return
71.55%
This Quarter Return
+6.38%
1 Year Return
+71.55%
3 Year Return
+1,109.63%
5 Year Return
–
10 Year Return
–
AUM
$405M
AUM Growth
+$48.5M
(+14%)
Cap. Flow
+$85.6M
Cap. Flow
% of AUM
21.14%
Top 10 Holdings %
Top 10 Hldgs %
49.16%
Holding
86
New
12
Increased
27
Reduced
11
Closed
19
Top Buys
| 1 |
Nuvalent
NUVL
|
$23.4M |
| 2 |
Erasca
ERAS
|
$17.9M |
| 3 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$10.8M |
| 4 |
UroGen Pharma
URGN
|
$9.96M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
$8.75M |
Top Sells
| 1 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$7.89M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
$5.98M |
| 3 |
Perspective Therapeutics
CATX
|
$5.49M |
| 4 |
Praxis Precision Medicines
PRAX
|
$5.1M |
| 5 |
Solid Biosciences
SLDB
|
$4.83M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Stoke Therapeutics
STOK
$1.08B
| $1.91M | 0.45% |
+141,518
| New | +$1.91M |
|
52
MacroGenics
MGNX
$123M
| $1.57M | 0.37% |
370,000
-108,079
| -23% | -$459K |
|
53
Modular Medical
MODD
$39.2M
| $1.42M | 0.34% |
900,000
| – | – |
|
54
Zura Bio
ZURA
$135M
| $1.15M | 0.27% |
328,504
| – | – |
|
55
Tarsus Pharmaceuticals
TARS
$2.42B
| $1.09M | 0.26% |
+40,000
| New | +$1.09M |
|
56
VYNE Therapeutics
VYNE
$7.91M
| $921K | 0.22% |
467,397
+381,014
| +441% | +$751K |
|
57
EyePoint Pharmaceuticals
EYPT
$819M
| $870K | 0.21% |
100,000
-147,968
| -60% | -$1.29M |
|
58
89bio
ETNB
$1.28B
| $739K | 0.17% |
92,298
| – | – |
|
|
MTEM
59
DELISTED
Molecular Templates, Inc.
MTEM
| $717K | 0.17% |
623,838
+269,230
| +76% | +$310K |
|
60
Fractyl Health
GUTS
$63.8M
| $712K | 0.17% |
166,666
| – | – |
|
61
Soleno Therapeutics
SLNO
$3.7B
| $612K | 0.14% |
+15,000
| New | +$612K |
|
62
Karyopharm Therapeutics
KPTI
$58.4M
| $485K | 0.11% |
37,231
| – | – |
|
63
Relmada Therapeutics
RLMD
$45.5M
| $298K | 0.07% |
99,379
| – | – |
|
64
Aligos Therapeutics
ALGS
$74.7M
| $229K | 0.05% |
26,221
| – | – |
|
65
Vaxcyte
PCVX
$4.17B
| $189K | 0.04% |
+2,500
| New | +$189K |
|
66
Rocket Pharmaceuticals, Inc. Warrant
RCKTW
$4.17M
| $6.36K | ﹤0.01% |
104,828
| – | – |
|
67
Adicet Bio
ACET
$59.4M
| – | – |
-331,279
| Closed | -$779K |
|
68
ALX Oncology
ALXO
$57.8M
| – | – |
0
| – | – |
|
69
Amylyx Pharmaceuticals
AMLX
$887M
| – | – |
-500,000
| Closed | -$1.42M |
|
70
Apogee Therapeutics
APGE
$2.21B
| – | – |
-50,000
| Closed | -$3.32M |
|
|
71
Crinetics Pharmaceuticals
CRNX
$3.23B
| – | – |
-127,835
| Closed | -$5.98M |
|
72
Cytokinetics
CYTK
$5.95B
| – | – |
-50,000
| Closed | -$3.51M |
|
73
DexCom
DXCM
$31.7B
| – | – |
-20,000
| Closed | -$2.77M |
|
74
Immunome
IMNM
$853M
| – | – |
-7,489
| Closed | -$185K |
|
75
Krystal Biotech
KRYS
$4.33B
| – | – |
-10,000
| Closed | -$1.78M |
|